DK2316466T3 - Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering - Google Patents

Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering

Info

Publication number
DK2316466T3
DK2316466T3 DK09075579.4T DK09075579T DK2316466T3 DK 2316466 T3 DK2316466 T3 DK 2316466T3 DK 09075579 T DK09075579 T DK 09075579T DK 2316466 T3 DK2316466 T3 DK 2316466T3
Authority
DK
Denmark
Prior art keywords
treatment
positive bacteria
gram
diseases
preparations
Prior art date
Application number
DK09075579.4T
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Boris Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2316466T3 publication Critical patent/DK2316466T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
DK09075579.4T 2001-12-11 2002-12-11 Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering DK2316466T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
EP02804652A EP1461054B1 (en) 2001-12-11 2002-12-11 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Publications (1)

Publication Number Publication Date
DK2316466T3 true DK2316466T3 (da) 2013-11-18

Family

ID=8183013

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02804652.2T DK1461054T3 (da) 2001-12-11 2002-12-11 Gram-positive bakteriepræparater til behandling af sygdomme omfattende en immundysregulering
DK09075579.4T DK2316466T3 (da) 2001-12-11 2002-12-11 Præparater af Gram-positive bakterier til behandling af sygdomme, der omfatter en immundysregulering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02804652.2T DK1461054T3 (da) 2001-12-11 2002-12-11 Gram-positive bakteriepræparater til behandling af sygdomme omfattende en immundysregulering

Country Status (17)

Country Link
US (3) US20060062807A1 (da)
EP (2) EP2316466B1 (da)
JP (2) JP4737586B2 (da)
KR (2) KR101048798B1 (da)
CN (1) CN1602199B (da)
AT (1) ATE466585T1 (da)
AU (1) AU2002356387C1 (da)
BR (1) BR0214902A (da)
CA (1) CA2469334C (da)
CY (1) CY1110727T1 (da)
DE (1) DE60236318D1 (da)
DK (2) DK1461054T3 (da)
ES (1) ES2345188T3 (da)
NZ (2) NZ533422A (da)
PT (1) PT1461054E (da)
SI (1) SI1461054T1 (da)
WO (1) WO2003049752A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316466B1 (en) 2001-12-11 2013-08-21 Institut Pasteur Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
DK1534330T3 (da) * 2002-09-06 2014-06-16 Ucl Business Plc Hele bakterieceller som immunmodulatorer
WO2005049056A2 (en) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
EP1730171A1 (en) 2004-02-19 2006-12-13 Ramot at Tel Aviv University Ltd. Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP5070051B2 (ja) * 2004-06-07 2012-11-07 クー バイオロジックス インク． 癌を治療するための細菌組成物
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
ATE447021T1 (de) 2004-06-24 2009-11-15 Yissum Res Dev Co Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
NZ576590A (en) * 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis
CA2629057A1 (en) * 2008-04-14 2009-10-14 Institut Pasteur Control of diseases associated with decrease of t-regulatory cells with a preparation of extended freeze-dried killed bacteria
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
JP6632607B2 (ja) 2014-05-02 2020-01-22 クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 抗微生物免疫修飾
CN109414463A (zh) * 2016-02-25 2019-03-01 托马斯·朱利叶斯·波洛迪 治疗慢性传染性疾病的组合物和方法
JP2022505421A (ja) * 2018-10-17 2022-01-14 サイバック インコーポレーテッド 肺疾病を処置および予防するための生きた生物学的製剤
ES2962407T3 (es) 2018-12-04 2024-03-18 Sabiotec Spin Off S L Inmunoestimulante para su uso contra patógenos
JP7441534B2 (ja) * 2019-01-09 2024-03-01 エムディー ヘルスケア インコーポレイテッド ロドコッカス属細菌由来ナノ小胞およびその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) * 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IN164864B (da) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
EP2316466B1 (en) 2001-12-11 2013-08-21 Institut Pasteur Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Also Published As

Publication number Publication date
CA2469334C (en) 2012-05-08
CY1110727T1 (el) 2015-06-10
JP2005516915A (ja) 2005-06-09
HK1067073A1 (en) 2005-04-01
US20060062807A1 (en) 2006-03-23
PT1461054E (pt) 2010-08-09
WO2003049752A2 (en) 2003-06-19
EP2316466B1 (en) 2013-08-21
AU2002356387B2 (en) 2007-09-13
KR20040080434A (ko) 2004-09-18
US8404250B2 (en) 2013-03-26
SI1461054T1 (sl) 2010-09-30
US7871627B2 (en) 2011-01-18
EP2316466A3 (en) 2012-04-11
CA2469334A1 (en) 2003-06-19
CN1602199B (zh) 2012-04-04
EP1461054A2 (en) 2004-09-29
DK1461054T3 (da) 2010-08-16
NZ533422A (en) 2008-03-28
KR20110028558A (ko) 2011-03-18
WO2003049752A3 (en) 2003-11-20
ATE466585T1 (de) 2010-05-15
US20100272756A1 (en) 2010-10-28
JP4737586B2 (ja) 2011-08-03
NZ555055A (en) 2010-06-25
US20070190076A1 (en) 2007-08-16
CN1602199A (zh) 2005-03-30
AU2002356387C1 (en) 2008-03-06
EP1461054B1 (en) 2010-05-05
ES2345188T3 (es) 2010-09-17
KR101048798B1 (ko) 2011-07-15
BR0214902A (pt) 2004-11-30
JP2011121977A (ja) 2011-06-23
DE60236318D1 (de) 2010-06-17
JP5417354B2 (ja) 2014-02-12
AU2002356387A1 (en) 2003-06-23
KR101124363B1 (ko) 2012-03-21
EP2316466A2 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
NO20034056D0 (no) Proliferative sykdommer
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE60233801D1 (de) Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
EP1262177A3 (en) Medical use of thyromimetic compounds to treat hair loss and compositions
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
WO2005013996A3 (en) 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
WO2003101397A3 (en) Tetravalent dengue vaccines
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
WO2002078742A3 (en) Methods and compositions for treatment of immune dysfunction disorders
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
WO2006004588A3 (en) Immunodynamic complexes and methods for using and preparing such complexes
WO2003013440A3 (en) Treatment and prevention of heat shock protein-associated diseases and conditions
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE458004T1 (de) Osteoprotegerin in milch
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
ATE339899T1 (de) Aromakonservierendes mittel
WO2002011549A3 (en) Treatment of mycobacterial infection
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections
WO2002069984A3 (de) Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen